Celltrion Inc

Celltrion established a subsidiary in Vietnam to secure approval for major products by year-end, aiming to enhance sales and marketing. The company plans to recruit local personnel for product marketing and build a network with Vietnamese bidding agencies. Celltrion targets the rapidly growing antibody drug sector in Vietnam, planning to market four key products from next year. By 2024, the company expects approval for three additional products, strengthening economic ties between Korea and Vietnam.

Celltrion plans to establish a Vietnamese corporation, obtain sales permits for major products including Remsima by year-end, and supply treatments across Vietnam. The company aims to expand its market share by focusing on proven products already popular in global markets.

Nemolizumab therapy showed continuous improvements in atopic dermatitis symptoms up to 56 weeks, with 47% achieving clear or almost clear skin and 73% improving EASI scores by 75%. Nemolizumab, an IL-31 receptor antagonist, demonstrated a favorable safety profile with no unexpected adverse events, positioning it as a valuable long-term treatment option for atopic dermatitis.

The EC approved Celltrion's ustekinumab biosimilar, SteQeyma, for chronic inflammatory diseases. Celltrion expanded Zymfentra access through Cigna and Express Scripts. The AAM held a policy briefing on biosimilar adoption barriers, focusing on patent issues.

IBD, including Crohn's disease and ulcerative colitis, lacks reliable predictors for treatment response. This Research Topic aims to identify and validate novel biomarkers to optimize personalized therapy, focusing on genetic, microbial, transcriptomic, and immunologic data.

Celltrion announced the full-scale launch of its CDMO business, aiming to secure new plants by year-end and invest trillions of won in a 180,000-liter production facility. The company, with its CMO know-how and global brand power, seeks to rival Lonza and offer customized services in the pharmaceutical supply cycle.

Prestige BioPharma received final EC approval for its Herceptin biosimilar, Tuznue, following EMA's CHMP recommendation. Tuznue is the third trastuzumab biosimilar approved in Europe, with Prestige aiming to expedite marketing for its Avastin biosimilar, HD204. Tuznue's approval marks Prestige's first milestone, with revenue expected post-launch. CEO Park So-yeon plans to meet potential partners at CPHI Milan 2024 and develop 15 biosimilar pipelines.

Yuhan Corporation tops net buying for top 1% investors at 9:30 a.m., driven by FDA approvals and collaborations. HPSP, a semiconductor equipment supplier, also sees net buying. HLB, Celltrion, and T&L experience net sales.

Goodwin's 1,600 lawyers globally excel in complex transactions, litigation, and advisory services across tech, life sciences, real estate, private equity, and finance, uniquely serving both innovators and investors.

Celltrion's Chairman Seo Jung-jin and CEO Seo Jin-seok presented at the 22nd Annual Global Healthcare Conference, outlining future growth strategies, including expanding into ADC and multi-antibody drugs, aiming for 22 biosimilar products by 2030, and potential new manufacturing facilities. Zimpentra's success in the U.S. boosts confidence in meeting this year's 3.5 trillion won sales target.